{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:21Z","timestamp":1789773321083,"version":"4.0.1"},"reference-count":149,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Toll-like receptors (TLR) belong to the pattern recognition receptors (PRR). TLR7 and the closely correlated TLR8 affiliate with toll-like receptors family, are located in endosomes. They recognize single-stranded ribonucleic acid (RNA) molecules and synthetic deoxyribonucleic acid (DNA)\/RNA analogs\u2014oligoribonucleotides. TLRs are primarily expressed in hematopoietic cells. There is compiling evidence implying that TLRs also direct the formation of blood cellular components and make a contribution to the pathogenesis of certain hematopoietic malignancies. The latest research shows a positive effect of therapy with TRL agonists on the course of hemato-oncological diseases. Ligands impact activation of antigen-presenting cells which results in production of cytokines, transfer of mentioned cells to the lymphoid tissue and co-stimulatory surface molecules expression required for T-cell activation. Toll-like receptor agonists have already been used in oncology especially in the treatment of dermatological neoplastic lesions. The usage of these substances in the treatment of solid tumors is being investigated. The present review discusses the direct and indirect influence that TLR7\/8 agonists, such as imiquimod, imidazoquinolines and resiquimod have on neoplastic cells and their promising role as adjuvants in anticancer vaccines.<\/jats:p>","DOI":"10.3390\/vaccines11020277","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:57:23Z","timestamp":1675058243000},"page":"277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of TRL7\/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies"],"prefix":"10.3390","volume":"11","author":[{"given":"Maria","family":"Le\u015bniak","sequence":"first","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Lipniarska","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Majka","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Kopyt","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature18847","article-title":"The microbiome and innate immunity","volume":"535","author":"Thaiss","year":"2016","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/intimm\/dxv013","article-title":"Dissecting the formation, structure and barrier function of the stratum corneum","volume":"27","author":"Matsui","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/imm.12597","article-title":"Innate immunity in vertebrates: An overview","volume":"148","author":"Romo","year":"2016","journal-title":"Immunology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.pcl.2019.06.011","article-title":"Innate Immunity","volume":"66","author":"Kaur","year":"2019","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern Recognition Receptors and Inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref_7","first-page":"1","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/bs.apcsb.2019.09.001","article-title":"Pattern recognition receptors as potential drug targets in inflammatory disorders","volume":"119","author":"McKernan","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like Receptors and the Control of Immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9912188","DOI":"10.1155\/2021\/9912188","article-title":"Toll-Like Receptor-Based Strategies for Cancer Immunotherapy","volume":"2021","author":"Pahlavanneshan","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2249.2005.02801.x","article-title":"Mammalian Toll-like receptors: To immunity and beyond","volume":"140","author":"Hopkins","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-Like Receptor Signaling Pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/molbev\/msy050","article-title":"Evolutionary Origins of Toll-like Receptor Signaling","volume":"35","author":"Brennan","year":"2018","journal-title":"Mol. Biol. Evol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Satoh, T., and Akira, S. (2016). Toll-Like Receptor Signaling and Its Inducible Proteins. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.MCHD-0040-2016"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1080\/21645515.2021.1964316","article-title":"Using PAMPs and DAMPs as adjuvants in cancer vaccines","volume":"17","author":"Sun","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: A double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.it.2017.08.002","article-title":"Exosomes, DAMPs and miRNA: Features of Stress Physiology and Immune Homeostasis","volume":"38","author":"Fleshner","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-981-10-5987-2_9","article-title":"TLR Agonists as Adjuvants for Cancer Vaccines","volume":"1024","author":"Li","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1021\/acs.jmedchem.1c00179","article-title":"Structure-Based Design of Highly Potent Toll-like Receptor 7\/8 Dual Agonists for Cancer Immunotherapy","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1084\/jem.20131044","article-title":"RNA recognition by human TLR8 can lead to autoimmune inflammation","volume":"210","author":"Guiducci","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.4049\/jimmunol.177.10.6584","article-title":"Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides","volume":"177","author":"Gorden","year":"2006","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.4161\/cc.6.23.5018","article-title":"TLR8: An Innate Immune Receptor in Brain, Neurons and Axons","volume":"6","author":"Ma","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"756315","DOI":"10.3389\/fcell.2021.756315","article-title":"Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies","volume":"9","author":"Farooq","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12915-019-0637-5","article-title":"Role of self-organising myddosome oligomers in inflammatory signalling by Toll-like receptors","volume":"17","author":"Gay","year":"2019","journal-title":"BMC Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_29","first-page":"372","article-title":"Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9","volume":"11","author":"Chuang","year":"2000","journal-title":"Eur. Cytokine Netw."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J. Autoimmun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108485","DOI":"10.1016\/j.celrep.2020.108485","article-title":"Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level","volume":"33","author":"Hagen","year":"2020","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e12776","DOI":"10.1111\/sji.12776","article-title":"Copy number of the X - linked genes TLR7 and CD40L influences innate and adaptive immune responses","volume":"90","author":"Sarmiento","year":"2019","journal-title":"Scand. J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Torcia, M.G., Nencioni, L., Clemente, A.M., Civitelli, L., Celestino, I., Limongi, D., Fadigati, G., Perissi, E., Cozzolino, F., and Garaci, E. (2012). Sex Differences in the Response to Viral Infections: TLR8 and TLR9 Ligand Stimulation Induce Higher IL10 Production in Males. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039853"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15838","DOI":"10.1073\/pnas.1001337107","article-title":"Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus","volume":"107","author":"Shen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"729233","DOI":"10.3389\/fimmu.2021.729233","article-title":"Sex Differences in Primary HIV Infection: Revisiting the Role of TLR7-Driven Type 1 IFN Production by Plasmacytoid Dendritic Cells in Women","volume":"12","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101299","DOI":"10.1016\/j.smim.2019.101299","article-title":"Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints","volume":"43","author":"Saleiro","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_38","first-page":"99","article-title":"Stromal Cells in the Tumor Microenvironment","volume":"Volume 1060","author":"Owens","year":"2018","journal-title":"Stromal Immunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"a026781","DOI":"10.1101\/cshperspect.a026781","article-title":"Tumor Microenvironment and Differential Responses to Therapy","volume":"7","author":"Hirata","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.1021\/acsnano.8b05893","article-title":"Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy","volume":"12","author":"Musetti","year":"2018","journal-title":"ACS Nano"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction","volume":"14","author":"Philip","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.molimm.2007.01.022","article-title":"TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance","volume":"44","author":"He","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12272-012-0802-7","article-title":"Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense","volume":"35","author":"Basith","year":"2012","journal-title":"Arch. Pharmacal Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2006.06.017","article-title":"Cox-2 Is Regulated by Toll-Like Receptor-4 (TLR4) Signaling: Role in Proliferation and Apoptosis in the Intestine","volume":"131","author":"Fukata","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"581837","DOI":"10.1155\/2010\/581837","article-title":"Toll-Like Receptors, Tissue Injury, and Tumourigenesis","volume":"2010","author":"Ioannou","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1021\/acs.nanolett.1c00209","article-title":"Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy","volume":"21","author":"Wei","year":"2021","journal-title":"Nano Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"a008250","DOI":"10.1101\/cshperspect.a008250","article-title":"Hematopoiesis","volume":"4","author":"Rieger","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2020.01236","article-title":"Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes","volume":"11","author":"Paracatu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jmb.2006.09.054","article-title":"Signaling through Toll-like Receptor 7\/8 Induces the Differentiation of Human Bone Marrow CD34+ Progenitor Cells along the Myeloid Lineage","volume":"364","author":"Sioud","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2011.10.005","article-title":"Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells","volume":"57","author":"Boiko","year":"2012","journal-title":"Cytokine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2011-03-344960","article-title":"Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes","volume":"118","author":"Schmid","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/eji.200737112","article-title":"TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80\/86+ DC capable of inducing a Th1-type response","volume":"37","author":"Sioud","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4049\/jimmunol.168.2.554","article-title":"Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines","volume":"168","author":"Zarember","year":"2002","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.exphem.2021.02.001","article-title":"TLR7\/8 agonist treatment induces an increase in bone marrow resident dendritic cells and hematopoietic progenitor expansion and mobilization","volume":"96","author":"Li","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fimmu.2016.00390","article-title":"The Role of Toll-Like Receptors in Hematopoietic Malignancies","volume":"7","author":"Monlish","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin Directed Therapy in Cutaneous T-Cell Lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: Updates and Review of Current Therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3816\/CLM.2007.n.037","article-title":"Synthetic Imidazoquinolines Potently and Broadly Activate the Cellular Immune Response of Patients with Cutaneous T-Cell Lymphoma: Synergy with Interferon-\u03b3 Enhances Production of Interleukin-12","volume":"7","author":"Wysocka","year":"2007","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3109\/10428194.2011.582202","article-title":"Synergistic enhancement of cellular immune responses by the novel Toll receptor 7\/8 agonist 3M-007 and interferon-\u03b3: Implications for therapy of cutaneous T-cell lymphoma","volume":"52","author":"Wysocka","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jdcr.2019.09.019","article-title":"Successful treatment of cutaneous adult T-cell leukemia\/lymphoma with imiquimod","volume":"5","author":"Messer","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_64","first-page":"460","article-title":"Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma with Topical Imiquimod","volume":"18","author":"Kubicki","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: A case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0019-5154.174085","article-title":"New Treatment Options for Mycosis Fungoides","volume":"61","author":"Shipman","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13555-019-00317-2","article-title":"Revisiting Imiquimod for Treatment of Folliculotropic Mycosis Fungoides: A Case Report and Review of the Literature","volume":"9","author":"Shalabi","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_68","first-page":"1","article-title":"Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines","volume":"18","author":"Such","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_69","first-page":"918","article-title":"The role of TLR8 signaling in acute myeloid leukemia differentiation","volume":"29","author":"Wang","year":"2014","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic Cells and Their Role in Immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.10.006","article-title":"Dendritic cells in hematological malignancies","volume":"108","author":"Galati","year":"2016","journal-title":"Crit. Rev. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"878","DOI":"10.18632\/oncotarget.27949","article-title":"Activation of plasmacytoid dendritic cells promotes AML-cell fratricide","volume":"12","author":"Fatehchand","year":"2021","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-010-0917-y","article-title":"Targeting Toll-like receptor 7\/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation","volume":"60","author":"Ancker","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00262-015-1680-x","article-title":"Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists","volume":"64","author":"Zhong","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2016.11.018","article-title":"Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and Fc\u03b3RIIIa-Triggered Responses","volume":"23","author":"Wagner","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.4049\/jimmunol.175.3.1636","article-title":"TLR7\/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-\u03b3 Production","volume":"175","author":"Hart","year":"2005","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4049\/jimmunol.1801026","article-title":"Costimulation through TLR2 Drives Polyfunctional CD8+ T Cell Responses","volume":"202","author":"Salerno","year":"2019","journal-title":"J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-009-0721-8","article-title":"The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells","volume":"59","author":"Smits","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e003385","DOI":"10.1136\/jitc-2021-003385","article-title":"Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56brightCD16\u2212 subset","volume":"10","author":"Veneziani","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2009.195","article-title":"A phase I\/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia","volume":"24","author":"Spaner","year":"2009","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2404061","article-title":"Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells","volume":"20","author":"Spaner","year":"2005","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4049\/jimmunol.176.6.3830","article-title":"Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity","volume":"176","author":"Tomic","year":"2006","journal-title":"J. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3109\/10428194.2012.741233","article-title":"Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine","volume":"54","author":"Wolska","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.niox.2008.04.017","article-title":"Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-\u03baB activation","volume":"19","author":"Hammadi","year":"2008","journal-title":"Nitric Oxide"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.4049\/jimmunol.1003438","article-title":"Chronic Exposure to a TLR Ligand Injures Hematopoietic Stem Cells","volume":"186","author":"Esplin","year":"2011","journal-title":"J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Ling, F., Wang, H.-C., and Sun, X.-H. (2013). Chronic TLR Signaling Impairs the Long-Term Repopulating Potential of Hematopoietic Stem Cells of Wild Type but Not Id1 Deficient Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055552"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2013.180","article-title":"Toll-like receptor alterations in myelodysplastic syndrome","volume":"27","author":"Wei","year":"2013","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yexcr.2015.12.008","article-title":"Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a \u03b2-arrestin 1 dependent mechanism","volume":"340","author":"Zeng","year":"2016","journal-title":"Exp. Cell Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Dimicoli, S., Wei, Y., Bueso-Ramos, C., Yang, H., Dinardo, C., Jia, Y., Zheng, H., Fang, Z., Nguyen, M., and Pierce, S. (2013). Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071120"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q\u2013 syndrome phenotype","volume":"16","author":"Starczynowski","year":"2009","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","article-title":"Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs","volume":"21","author":"Muto","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exphem.2022.03.011","article-title":"Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes","volume":"110","author":"Paracatu","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4049\/immunohorizons.2000002","article-title":"TLR7 and TLR8 Differentially Activate the IRF and NF-\u03baB Pathways in Specific Cell Types to Promote Inflammation","volume":"4","author":"Bender","year":"2020","journal-title":"Immunohorizons"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Bohnhorst","year":"2006","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1084\/jem.20050630","article-title":"RNA-associated autoantigens activate B cells by combined B cell antigen receptor\/Toll-like receptor 7 engagement","volume":"202","author":"Lau","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.4049\/jimmunol.1601746","article-title":"Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement","volume":"198","author":"Schuh","year":"2017","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Abdi, J., Mutis, T., Garssen, J., and Redegeld, F. (2013). Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060671"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","article-title":"Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors","volume":"20","author":"Jego","year":"2006","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"114992","DOI":"10.1016\/j.bcp.2022.114992","article-title":"Toll-like receptors: New targets for multiple myeloma treatment","volume":"199","author":"Akesolo","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.critrevonc.2010.12.001","article-title":"The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma","volume":"80","author":"Abdi","year":"2011","journal-title":"Crit. Rev. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2008.07475.x","article-title":"Expression and function of toll like receptors in chronic lymphocytic leukaemia cells","volume":"144","author":"Muzio","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_104","first-page":"1132","article-title":"Toll-like receptors on B-CLL cells: Expression and functional consequences of their stimulation","volume":"126","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2014.00367","article-title":"Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fcell.2020.00262","article-title":"A Dual TLR7\/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation","volume":"8","author":"An","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","article-title":"Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies","volume":"11","author":"Gummadi","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Brenner, A.K., and Bruserud, \u00d8. (2019). Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype. Cancers, 11.","DOI":"10.3390\/cancers11070973"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07858.x","article-title":"Toll-like Receptors (TLRs) are expressed by myeloid leukaemia cell lines, but fail to trigger differentiation in response to the respective TLR ligands","volume":"147","author":"Okamoto","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"120601","DOI":"10.1016\/j.biomaterials.2020.120601","article-title":"Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes","volume":"268","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jconrel.2020.11.013","article-title":"Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy","volume":"330","author":"Zhang","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.02.025","article-title":"Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies","volume":"47","author":"Pockros","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_115","first-page":"e93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Yao","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.mtbio.2022.100238","article-title":"In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy","volume":"14","author":"Li","year":"2022","journal-title":"Mater. Today Bio"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e1419113","DOI":"10.1080\/2162402X.2017.1419113","article-title":"Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial","volume":"7","author":"Teulings","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/ijgc-2021-003262","article-title":"The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions","volume":"32","author":"Preti","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(22)00469-X","article-title":"Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: A multicentre, randomised, phase 3, non-inferiority trial","volume":"399","author":"Trutnovsky","year":"2022","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"250.e1","DOI":"10.1016\/j.ajog.2022.04.012","article-title":"The Paget Trial: Topical 5% imiquimod cream for noninvasive vulvar Paget disease","volume":"227","author":"Bulten","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2022.05.010","article-title":"Vulvar Paget\u2019s disease: Outcomes of 51 patients treated with imiquimod cream","volume":"163","author":"Borella","year":"2022","journal-title":"Maturitas"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000496052","article-title":"Malignant Melanoma Treated with Topical Imiquimod: A Bespoke Treatment That Spared the Amputation","volume":"11","author":"Verga","year":"2019","journal-title":"Case Rep. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13555-020-00473-w","article-title":"Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin","volume":"11","author":"Nahm","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/09546634.2021.1962001","article-title":"Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment","volume":"33","author":"Kwak","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/cam4.402","article-title":"Using topical imiquimod for the management of positive in situ margins after melanoma resection","volume":"4","author":"Pandit","year":"2015","journal-title":"Cancer Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1097\/SAP.0000000000001840","article-title":"An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod","volume":"82","author":"Tsay","year":"2019","journal-title":"Ann. Plast. Surg."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.0022-202X.2004.22528.x","article-title":"Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier Imiquimod","volume":"122","author":"Wienrich","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_128","first-page":"T407","article-title":"[Art\u00edculo traducido] Serie de 14 casos de tratamiento con imiquimod t\u00f3pico al 5% en lentigo maligno: Modalidades terap\u00e9uticas y claves para detectar recidivas","volume":"113","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"van de Sande, A.J.M., Koeneman, M.M., Gerestein, C.G., Kruse, A.J., van Kemenade, F.J., and van Beekhuizen, H.J. (2018). TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): A study protocol for a randomized controlled trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4510-7"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0000000000000414","article-title":"Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study","volume":"45","author":"Hendriks","year":"2022","journal-title":"J. Immunother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2022.01.033","article-title":"Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial","volume":"165","author":"Polterauer","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09760-3","article-title":"Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice","volume":"10","author":"Yue","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/acs.bioconjchem.1c00139","article-title":"Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7\/8 Agonist to Repolarize Ovarian Tumors\u2019 Microenvironment","volume":"32","author":"Kang","year":"2021","journal-title":"Bioconjugate Chem."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Pauli, G., Chao, P.-H., Qin, Z., B\u00f6ttger, R., Lee, S.E., and Li, S.-D. (2021). Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101696"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jconrel.2022.09.009","article-title":"Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia","volume":"350","author":"Meng","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e2004559","DOI":"10.1002\/adma.202004559","article-title":"Biopolymer Immune Implants\u2019 Sequential Activation of Innate and Adaptive Immunity for Colorectal Cancer Postoperative Immunotherapy","volume":"33","author":"Ji","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/acsnano.0c08384","article-title":"Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice","volume":"15","author":"Wagner","year":"2021","journal-title":"ACS Nano"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"10979","DOI":"10.1021\/acsnano.2c03395","article-title":"Immunosonodynamic Therapy Designed with Activatable Sonosensitizer and Immune Stimulant Imiquimod","volume":"16","author":"Lei","year":"2022","journal-title":"ACS Nano"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2147\/IJN.S301552","article-title":"Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment","volume":"16","author":"Lin","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1021\/acs.nanolett.2c00500","article-title":"Surgical Tumor-Derived Photothermal Nanovaccine for Personalized Cancer Therapy and Prevention","volume":"22","author":"Li","year":"2022","journal-title":"Nano Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.7150\/ijms.49983","article-title":"Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia","volume":"17","author":"Zhong","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.leukres.2018.03.002","article-title":"An autologous tumor vaccine for CLL","volume":"68","author":"Zhu","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/leu.2016.352","article-title":"A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells","volume":"31","author":"Cheadle","year":"2016","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-83005-6","article-title":"Novel TLR 7\/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)","volume":"11","author":"Khanna","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_145","unstructured":"Taghiloo, S., Ajami, A., Alizadeh-Navaei, R., Zaboli, E., and Asgarian-Omran, H. (2022). Treatment by PI3K\/MTOR Inhibitor BEZ235 Combined with TLR-7\/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells. Iran. J. Immunol., 1."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0121-9","article-title":"Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma","volume":"8","author":"Zhu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1182\/bloodadvances.2020003055","article-title":"TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signaling","volume":"5","author":"Lubin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Assi, R., and Salman, H. (2022). Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare. Cells, 11.","DOI":"10.3390\/cells11243971"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e202113341","DOI":"10.1002\/anie.202113341","article-title":"Design, Synthesis, and Targeted Delivery of an Immune Stimulant that Selectively Reactivates Exhausted CAR T Cells","volume":"61","author":"Napoleon","year":"2022","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:35Z","timestamp":1760120255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":149,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020277"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020277","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}